A novel immune-based therapy shows 100% response rates in newly diagnosed multiple myeloma patients, highlighting its potential as a frontline treatment.
Marc Raab, MD
Marc Raab, MD, is a professor of medicine and clinical director of the Heidelberg Myeloma Center Department of Medicine V, Heidelberg University Hospital.
Articles by Marc Raab, MD
A new study reveals a groundbreaking treatment for newly diagnosed multiple myeloma, achieving 100% response rates and minimal residual disease negativity.
Latest Updated Articles
Teclistamab Combos Are Encouraging in Frontline MyelomaPublished: October 13th 2025 | Updated:
Raab: Utilizing Early Bispecific Combos in MyelomaPublished: November 17th 2025 | Updated: